WO2003035616A3 - Tyrosine kinase inhibitors - Google Patents

Tyrosine kinase inhibitors Download PDF

Info

Publication number
WO2003035616A3
WO2003035616A3 PCT/US2002/033921 US0233921W WO03035616A3 WO 2003035616 A3 WO2003035616 A3 WO 2003035616A3 US 0233921 W US0233921 W US 0233921W WO 03035616 A3 WO03035616 A3 WO 03035616A3
Authority
WO
WIPO (PCT)
Prior art keywords
compounds
tyrosine kinase
kinase inhibitors
present
receptor
Prior art date
Application number
PCT/US2002/033921
Other languages
French (fr)
Other versions
WO2003035616A2 (en
Inventor
B Wesley Trotter
Ian M Bell
Original Assignee
Merck & Co Inc
B Wesley Trotter
Ian M Bell
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck & Co Inc, B Wesley Trotter, Ian M Bell filed Critical Merck & Co Inc
Priority to AU2002348020A priority Critical patent/AU2002348020A1/en
Publication of WO2003035616A2 publication Critical patent/WO2003035616A2/en
Publication of WO2003035616A3 publication Critical patent/WO2003035616A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms

Abstract

The present invention relates to compounds that are capable of inhibiting, modulating and/or regulating signal transduction of both receptor-type and non-receptor type tyrosine kinases. The compounds of the instant invention possess a core structure that comprises a 2-tert-butoxycarbonyl or 2-tertbutyl-aminocarbonyl pyrrole. The present invention is also related to the pharmaceutically acceptable salts, hydrates and stereoisomers of these compounds.
PCT/US2002/033921 2001-10-25 2002-10-21 Tyrosine kinase inhibitors WO2003035616A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2002348020A AU2002348020A1 (en) 2001-10-25 2002-10-21 Tyrosine kinase inhibitors

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US34290001P 2001-10-25 2001-10-25
US60/342,900 2001-10-25

Publications (2)

Publication Number Publication Date
WO2003035616A2 WO2003035616A2 (en) 2003-05-01
WO2003035616A3 true WO2003035616A3 (en) 2003-10-23

Family

ID=23343769

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2002/033921 WO2003035616A2 (en) 2001-10-25 2002-10-21 Tyrosine kinase inhibitors

Country Status (2)

Country Link
AU (1) AU2002348020A1 (en)
WO (1) WO2003035616A2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9381246B2 (en) 2013-09-09 2016-07-05 Triact Therapeutics, Inc. Cancer therapy

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7538231B2 (en) * 2003-07-24 2009-05-26 Merck & Co, Inc. Tyrosine kinase inhibitors
WO2007035744A1 (en) 2005-09-20 2007-03-29 Osi Pharmaceuticals, Inc. Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors
US20120189641A1 (en) 2009-02-25 2012-07-26 OSI Pharmaceuticals, LLC Combination anti-cancer therapy
JP2012519170A (en) 2009-02-26 2012-08-23 オーエスアイ・ファーマシューティカルズ，エルエルシー INSITU method for monitoring EMT status of tumor cells in vivo
WO2010099364A2 (en) 2009-02-27 2010-09-02 Osi Pharmaceuticals, Inc. Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation
EP2401614A1 (en) 2009-02-27 2012-01-04 OSI Pharmaceuticals, LLC Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation
WO2010099138A2 (en) 2009-02-27 2010-09-02 Osi Pharmaceuticals, Inc. Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation
WO2010146059A2 (en) 2009-06-16 2010-12-23 F. Hoffmann-La Roche Ag Biomarkers for igf-1r inhibitor therapy
CA2783665A1 (en) 2010-03-03 2011-09-09 OSI Pharmaceuticals, LLC Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors
US20110275644A1 (en) 2010-03-03 2011-11-10 Buck Elizabeth A Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors
EP2544672A1 (en) 2010-03-09 2013-01-16 OSI Pharmaceuticals, LLC Combination anti-cancer therapy
US20120214830A1 (en) 2011-02-22 2012-08-23 OSI Pharmaceuticals, LLC Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors in hepatocellular carcinoma
EP2702173A1 (en) 2011-04-25 2014-03-05 OSI Pharmaceuticals, LLC Use of emt gene signatures in cancer drug discovery, diagnostics, and treatment
WO2013152252A1 (en) 2012-04-06 2013-10-10 OSI Pharmaceuticals, LLC Combination anti-cancer therapy
AU2014223548A1 (en) 2013-02-26 2015-10-15 Triact Therapeutics, Inc. Cancer therapy
CN104961669B (en) * 2015-03-18 2018-02-13 河南农业大学 The preparation method of the pyrrole carboxylic acid ester of 2 methyl of N alkyl, 5 formoxyl 3 and its application in perfuming cigarette
US11161823B2 (en) 2019-03-11 2021-11-02 National Guard Health Affairs Anticancer 1,3-dioxane-4,6-dione derivatives and method of combinatorial synthesis thereof

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000038519A1 (en) * 1998-12-31 2000-07-06 Sugen, Inc. 3-heteroarylidenyl-2-indolinone compounds for modulating protein kinase activity and for use in cancer chemotherapy

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000038519A1 (en) * 1998-12-31 2000-07-06 Sugen, Inc. 3-heteroarylidenyl-2-indolinone compounds for modulating protein kinase activity and for use in cancer chemotherapy

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9381246B2 (en) 2013-09-09 2016-07-05 Triact Therapeutics, Inc. Cancer therapy

Also Published As

Publication number Publication date
WO2003035616A2 (en) 2003-05-01
AU2002348020A1 (en) 2003-05-06

Similar Documents

Publication Publication Date Title
WO2004014300A3 (en) Tyrosine kinase inhibitors
WO2004014851A3 (en) Tyrosine kinase inhibitors
WO2003035615A3 (en) Tyrosine kinase inhibitors
WO2003035616A3 (en) Tyrosine kinase inhibitors
WO2003035614A3 (en) Tyrosine kinase inhibitors
WO2003035619A8 (en) Tyrosine kinase inhibitors
WO2002046183A3 (en) Indazolyl-substituted pyrroline compounds as kinase inhibitors
WO2004031401A3 (en) Novel tyrosine kinases inhibitors
WO2001064681A3 (en) 3-(pyrolyllactone)-2-indolinone compounds as kinase inhibitors
WO2001060814A3 (en) Pyrrole substituted 2-indolinone protein kinase inhibitors
WO2006050109A3 (en) Novel kinase inhibitors
WO2000043373A3 (en) Kinase inhibitors
WO2006047479A3 (en) C-fms kinase inhibitors
WO2000002576A3 (en) Egf-genistein for prevention of restenosis
WO2004096795A3 (en) C-fms kinase inhibitors
WO2004009597A3 (en) Pyrazolopyrimidines as protein kinase inhibitors
WO2006047503A3 (en) Inhibitors of c-fms kinase
WO2001019828A3 (en) Kinase inhibitors as therapeutic agents
MXPA03010207A (en) Novel 4-anilinoquinoline-3-carboxamides.
AU2001288374A1 (en) Substituted oxindole derivatives as tyrosine kinase inhibitors
WO2002016312A3 (en) NOVEL COMPOUNDS INHIBITING FACTOR Xa ACTIVITY
AU5215700A (en) Substituted indolinone as tyrosine kinase inhibitors
WO2002081728A3 (en) Quinoline inhibitors of hyak1 and hyak3 kinases
WO2003086315A3 (en) Tyrosine kinase inhibitors
WO2005009373A3 (en) Tyrosine kinase inhibitors

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LU MC NL PT SE SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP